Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Dynamics, AstraZeneca Ink Stem Cell Partnership

NEW YORK (GenomeWeb News) – Cellular Dynamics today said that it will collaborate with AstraZeneca on developing new human induced pluripotent stem cells for therapeutic discovery screening applications.

Cellular Dynamics said that under the "Center of Excellence" agreement AstraZeneca will use the firm's iCell and MyCell products for iPSC reprogramming and differentiation, and the firms will collaborate on the development of one or more novel cell types. Specifically, Cellular Dynamics said that AstraZeneca will use the MyCell technology to genetically engineer and manufacture cells from specific patient groups for use as in vitro disease models.

Cellular Dynamics CEO Bob Palay noted that the deal with AstraZeneca is the firm's third Center of Excellence agreement with a global pharmaceutical company.

Further terms of the alliance were not disclosed.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.